Slide 1: VenoValve First-in-Man
July 25, 2019 VenoValve. First-in-Man Bogota, Colombia JORGE H. ULLOA, MD., FACS. CIRUJANO VASCULAR FUNDACION SANTA FE DE BOGOTA PROFESOR DE CIRUGIA VASCULAR UNIVERSIDAD DE LOS ANDES Universidad de los Andes Fundaci6n . Santa Fe de Bogota
Slide 2: Cautionary Note on Forward-Looking Statements
HANCOCK JAFFE LABORATORIES INC Cautionary Note on Forward-Looking Statements This presentation, press release and any statements of stockholders, directors, employees, representatives and partners of Hancock Jaffe Laboratories, Inc. (the “Company”) related thereto contain, or may contain, among othe
Slide 3: Financial Disclosure
Financial Disclosure Principal Investigator Support HANCOCK JAFFE LABORATORIES INC Funding for First-in-Man Research Nasdaq: HJLI |SOcIVECC July 25, 2019
Slide 4: CVI
CVI >More than 1.2 million people in the U.S. have C6 disease with ulcers according to the latest Medicare database > Approximately 2.4 million people in the U.S. have C4 to C6 disease caused by valvular incompetence >The average ulcer patient in the U.S. spends $30,000 per year on wound care Direct
Slide 5: VenoValve by Hancock Jaffe Laboratories
VenoValvee by Hancock Jaffe Laboratories »Porcine aortic leaflet; mono cusp »Stainless steel frame; monofilament »Opens and closes against native vessel >»21mm length; 10mm diameter >»Same day surgery July 25, 2019
Slide 6: Pre-Op Duplex Scan
Pre-Op Duplex Scan GD) |socivece , ey Sa July 25, 2019
Slide 7: July 25, 2019
July 25, 2019
Slide 8: Post-Op Duplex scan
Post-Op Duplex scan —P) |SOCIVECC - GBH |socivecc July 25, 2019
Slide 9: VenoValve — FIM: Study End Points
VenoValve — FIM: STUDY END POINTS >Safety - infection; PE; native vein injury; allergic reaction >Reflux - measured by doppler with ultrasound »Venous Clinical Severity Score (VCSS) »Visual Analogue Scale(VAS) Score - intensity and frequency of pain July 25, 2019
Slide 10: Results of 90 day FIM
Results of 90 day FIM July 25, 2019
Slide 11: VenoValve: FIM - Patients - Safety
VenoValve: FIM - 5 Patients - Safety Patient #1 90 Days Patient #2 90 Days Patient #3 90 Days Patient #4 90 Days Patient #5 90 Days No Serious Device Related Adverse Events VenoValve® First in-Man Study, Bogota, Colombia JORGE H. ULLOA, MD.,FACS. — July 25,2019 SOCIVECC SDCVE Hancock Jaffe Laborator
Slide 12: Patient #1 Reflux 73% Reduction
Patient #1 Reflux 90 Days 73% Reduction =--> Normal 0.5 nnn nn 0 Pre-Op Surgery 14 Days 30 Days 60 days 90 Days vcss VAS 57% Reduction Symptoms a" 63% Reduction Pain Ono a BR Pre-Op 30 Days 60 Days 90 Days Pre-Op 30 Days 60 Days 90 Days VenoValve® First in-Man Study, Bogota, Colombia JORGE H. ULLOA,
Slide 13: Patient #2 Reflux 80% Reduction
Patient #2 Reflux 90 Days 80% Reduction 60 days 90 Days Surgery 14 Days 30 Days VAS vcss 44% Reduction Pain 60% Reduction Symptoms __,, 5 a 8 oo 6 4 3 0 0 Pre-Op 30 Days 60 Days 90 Days Pre-Op 30 Days 60 Days 90 Days JORGE H. ULLOA, MD.,FACS. — July25,2019 SOCIVECC SDCVE @Hancock Jaffe Laboratories,
Slide 14: Patient #3 Reflux 33% Reduction
Patient #3 Reflux 90 Days 2 33% Reduction SSeS SSeS eS ---> Normal Pre-Op Surgery 14 Days 30 Days 60 days 90 days VAS 17% Reduction Pain vcss 56% Reduction Symptoms SCH OD © ON AR OO Pre-Op 30 Days 60 Days 90 Days Pre-Op 30 Days 60 Days 90 Days JORGE H. ULLOA, MD.,FACS. — July25,2019 SOCIVECC SDCVE
Slide 15: Patient #4 Reflux 65% Reduction
Patient #4 Reflux 90 Days 65% Reduction Normal Pre-Op Surgery 14 Days 30 Days 60 Days 90 Days vcss VAS 5% Reduction Symptoms. 3 33% Reduction Pain 9 5 TT "l[ i a 2 0 0 Pre-Op 30 Days 60 Days 90 Days Pre-Op 30 Days 60 Days 90 Days JORGE H. ULLOA, MD.,FACS. — July25,2019 SOCIVECC SDCVE @Hancock Jaffe
Slide 16: Patient #5 Reflux
Reflux 20% Increase Patient #5 90 Days 2 Occluded 15 foe ----> Normal 30 Days 60 Days 90 Days Pre-Op Surgery 14 Days vcss VAS 62% Reduction Symptoms 17 % Reduction Pain 13 oo 9 4 0 Oo WwW OM © Pre-Op 30 Days 60 Days 90 Days Pre-Op 30 Days 60 Days 90 Days JORGE H. ULLOA, MD.,FACS. — July25,2019 SOCIV
Slide 17: VenoValve - Reflux
VenoValve - Reflux Patient #1 Patient #2 2 73% Reduction Reflux 2 80% Reduction Reflux 125, 15 4 1 (ee => Normal 0.5 in" wae e eee eee eee eesceeeeesss Tremecii N jormal ie} 0 Pre-Op Surgery 14Days 30Days 60days 90 Pre-Op Surgery 14Days 30Days 60days 90 Days Patient #3 Patient #4 - 33% Reduction Ref
Slide 18: VenoValve: VCSS
VenoValve: VCSS Patient #1 1a 57% Reduction Symptoms Pre-Op 30 Days 60 Days Patient #3 56% Reduction Symptoms a, = Pre-Op 30 Days ow ® © 60 Days 90 Days VenoValve® First in-Man Study, Bogota, Colombia 90 Days JORGE H. ULLOA, MD.,FACS. Patient #2 60% Reduction Symptoms Pre-Op 30 Days 60 Days 90 Days
Slide 19: VenoValve: VAS
VenoValve: VAS Patient #1 63% Reduction Pain SS Pre-Op 30 Days 60 Days 90 Days Patient #3 17% Reduction Pain iT Reduction Pain Pre-Op 30 Days 60 Days 90 Days VenoValve® First in-Man Study, Bogota, Colombia 14 ON BR OO — Pre-Op Pre-Op JORGE H. ULLOA, MD.,FACS. Patient #2 44% Reduction Pain 30 Days CW
Slide 20: First-in-Human Data - Endpoints - Days
FIRST-IN-HUMAN DATA - ENDPOINTS - 90 DAYS REFLUX vcss VAS (% Decrease) (% Decrease) (% Decrease) Patient #1 Patient #2 Patient #3 Patient #4 AVERAGE 68% 49% 39% VenoValve® First in-Man Study, Bogota, Colombia JORGE H. ULLOA, MD.,FACS. — July 25,2019 SOCIVECC SDCVE Hancock Jaffe Laboratories, Inc.
Slide 21: Conclusion
Conclusion >» No device related adverse events have been seen at 90 days >» At 90 days, the patients with VenoValve implant demonstrated > Improvement in axial reflux in the deep venous system > Improvement in Clinical evaluation of the patient by VCSS scores > Improvement in pain in the patients wi
Slide 22: July 25,2019 SOCIVECC SDCVE Hancock
VenoValve® First in-Man Study, Bogota, Colombia JORGE H. ULLOA, MD.,FACS. — July 25,2019 SOCIVECC SDCVE Hancock Jaffe Laboratories, Inc.
Slide 23: SOCIVECC
SOCIVECC July 25, 2019